SG11201913540VA - Anti-Podoplanin Antibody - Google Patents

Anti-Podoplanin Antibody

Info

Publication number
SG11201913540VA
SG11201913540VA SG11201913540VA SG11201913540VA SG11201913540VA SG 11201913540V A SG11201913540V A SG 11201913540VA SG 11201913540V A SG11201913540V A SG 11201913540VA SG 11201913540V A SG11201913540V A SG 11201913540VA SG 11201913540V A SG11201913540V A SG 11201913540VA
Authority
SG
Singapore
Prior art keywords
podoplanin antibody
podoplanin
antibody
Prior art date
Application number
SG11201913540VA
Inventor
Nobuhiko Gyobu
Naoya Fujita
Mamoru Kakino
Ai Kawashima
Shinya Fujihara
Naoki Goda
Original Assignee
Japanese Found For Cancer Res
Api Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japanese Found For Cancer Res, Api Co Ltd filed Critical Japanese Found For Cancer Res
Publication of SG11201913540VA publication Critical patent/SG11201913540VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201913540VA 2019-03-15 2019-06-14 Anti-Podoplanin Antibody SG11201913540VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019048861 2019-03-15
PCT/JP2019/023682 WO2020188836A1 (en) 2019-03-15 2019-06-14 Anti-podoplanin antibody

Publications (1)

Publication Number Publication Date
SG11201913540VA true SG11201913540VA (en) 2020-10-29

Family

ID=72520770

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201913540VA SG11201913540VA (en) 2019-03-15 2019-06-14 Anti-Podoplanin Antibody

Country Status (6)

Country Link
JP (1) JP2020150947A (en)
KR (1) KR20210141794A (en)
CN (1) CN113646332B (en)
SG (1) SG11201913540VA (en)
TW (1) TW202034953A (en)
WO (1) WO2020188836A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5604726B2 (en) * 2009-07-07 2014-10-15 国立大学法人京都大学 Immunoassay for podoplanin
EP2484697B1 (en) * 2009-09-30 2016-09-14 Fujifilm RI Pharma Co., Ltd. Anti-podoplanin antibody, and pharmaceutical composition containing anti-podoplanin antibody
JP6039428B2 (en) * 2010-03-04 2016-12-07 シムフォゲン・アクティーゼルスカブSymphogen A/S Anti-HER2 antibodies and compositions
KR101981342B1 (en) * 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea antibodies
US10227407B2 (en) * 2013-10-10 2019-03-12 Yukinari Kato Anti-podoplanin antibody
EP3256494A4 (en) * 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
EP3323831B1 (en) 2015-07-15 2023-04-12 Japanese Foundation For Cancer Research Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor
JP2018168068A (en) * 2015-08-10 2018-11-01 国立大学法人東北大学 Anti-podoplanin antibody and antibody-drug complex
CN106947744B (en) * 2017-03-14 2020-05-05 福州迈新生物技术开发有限公司 Hybridoma cell strain secreting monoclonal antibody against podophyllum protein and application thereof
WO2018179302A1 (en) * 2017-03-30 2018-10-04 国立大学法人東北大学 Anti-podoplanin antibody

Also Published As

Publication number Publication date
TW202034953A (en) 2020-10-01
WO2020188836A1 (en) 2020-09-24
CN113646332B (en) 2024-08-23
JP2020150947A (en) 2020-09-24
CN113646332A (en) 2021-11-12
KR20210141794A (en) 2021-11-23

Similar Documents

Publication Publication Date Title
IL279321A (en) Anti-sirpα antibody
SG11202106214YA (en) Novel anti-ccr8 antibody
IL280780A (en) Anti-tigit antibodies
IL280013A (en) Anti-il36r antibodies
IL279352A (en) Il-11ra antibodies
IL289112A (en) Anti-tigit antibodies
IL278010A (en) Galectin-10 antibodies
IL291068A (en) Anti-cd73 antibodies
IL277030A (en) Antibodies
GB202110263D0 (en) Anti-btla antibodies
IL284584A (en) Anti-tigit antibodies
ZA202101177B (en) Anti-btla antibody
GB201811368D0 (en) Antibody
GB201817172D0 (en) Antibody
GB201905150D0 (en) Ant-ige antibodies
IL281594A (en) Anti-klrg1 antibodies
GB2581174B (en) Antibodies against hEPCR
ZA202108836B (en) Anti-epha4 antibody
EP4083211A4 (en) Anti-cdcp1 antibody
GB201806084D0 (en) Antibodies
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
GB201919062D0 (en) Antibody